Daily Chart

Bristol-myers Squibb Co (BMY) Financial News - Fed Dissenters, Euro Tax, Zynga, Apple, Melanoma: Compliance

Bristol-myers Squibb Co (BMY)

Fed Dissenters, Euro Tax, Zynga, Apple, Melanoma: Compliance

Quote: deathsBristol-Myers Squibb Co. (BMY)’s Yervoy, cleared in March as the first treatment proven to extend lives of advanced melanoma patients. Jack ScannellLondonNew York, may earn $1.5 billion from Yervoy in 2015, according to the average estimate of three analysts surveyed by Bloomberg. Whiskey, Wine Fraud on Americans Brings 5-Year Term for Briton A British man who defrauded American and Canadian investors of about 30 million pounds ($49 million) through investment schemes tied to wine, whiskey, cognac and champagne was sentenced to 5 years in prison. Serious Fraud Office, which prosecuted the case, said in a statement yesterday. Gunter’s U.K.-based company called the Hallmark Partnership, and later Vintage Hallmark Plc, operated like a Ponzi scheme, prosecutors said. Gunter promised investors high rates of return over short periods of time, including a 50 percent return over 10 months for a champagne investment, and a 110 percent return over three months from whiskey investments. Gunter’s 5-year sentence was handed down in June and couldn’t be made public until yesterday because of reporting restrictions related to Gunter’s co-defendant Robin Grove’s trial. Gunter had previously been found guilty for his involvement in a similar wine investment scheme in 2008. He was sentenced to 4 1/2 years in prison for that fraud. He is to serve the terms concurrently. DLF Fined 6.3 Billion Rupees by India’s Antitrust Agency DLF Ltd. (DLFU) 6.3 billion rupees ($139 million) for “abuse of dominance” related to the sale of apartments. DLF, India’s largest developer, has received the regulator’s order and will examine all options including an appeal to the Competition Appellate Tribunal, the New Delhi- based company said in a statement yesterday. The Belaire Owners’ Association, representing buyers at the Belaire housing complex in DLF City in Gurgaon, had complained tha...
Open whole article (external link)

Other Financial and Stock Market News concerning Bristol-myers Squibb Co

Bristol-myers Squibb Co Stock Summary

Bristol-Myers Squibb Company, a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical needs, such as cardiovascular disease, mental illness, cancer, HIV/AIDS, hepatitis B and C, rheumatoid arthritis, type 2 diabetes, solid organ transplantation, and Alzheimer's disease. Its principal products include PLAVIX for protection against fatal or non-fatal heart attack or stroke; AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy; ABILIFY, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and REYATAZ for the treatment of HIV. The company?s principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in adults; IXEMPRA to treat breast cancer; ORENCIA to severe rheumatoid arthritis in adults; and ONGLYZA for the treatment of type 2 diabetes. Its products under Phase III clinical trials include ELIQUIS to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; NULOJIX to prevent solid organ transplant rejection; Brivanib to block the VEGF and the FGF receptors; Dapagliflozin to treat diabetes; YERVOY to treat metastatic melanoma; and Necitumumab for anticancer treatment. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with sanofi-aventis; Pfizer, Inc.; AstraZeneca PLC; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; and Gilead Sciences, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.